Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells
Open Access
- 7 February 2013
- journal article
- Published by Springer Nature in Cancer Cell International
- Vol. 13 (1) , 10
Abstract
This study examined whether combining paclitaxel (taxol) with a novel epigenetic agent phenethyl isothiocyanate (PEITC) will yield a synergistic effect on inhibiting breast cancer cells. Two drug-resistant breast cancer cell lines, MCF7 and MDA-MB-231, were treated with PEITC and taxol. Cell growth, cell cycle, and apoptosis were examined. The combination of PEITC and taxol significantly decreased the IC50 of PEITC and taxol over each agent alone. The combination also increased apoptosis by more than two fold over each single agent in both cell lines. A significant increase of cells in the G2/M phases was detected. In conclusion, the combination of PEITC and taxol exhibits a synergistic effect on growth inhibition in breast cancer cells. This combination deserves further study in vivo.Keywords
This publication has 49 references indexed in Scilit:
- Polo-like kinase 1 as target for cancer therapyExperimental Hematology & Oncology, 2012
- SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cellsJournal of Hematology & Oncology, 2012
- CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology & Oncology, 2012
- Targeted drug delivery for cancer therapy: the other side of antibodiesJournal of Hematology & Oncology, 2012
- Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemiaJournal of Hematology & Oncology, 2012
- Current management and prognostic features for gastrointestinal stromal tumor (GIST)Experimental Hematology & Oncology, 2012
- Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisExperimental Hematology & Oncology, 2012
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARPJournal of Hematology & Oncology, 2011
- Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumorsJournal of Hematology & Oncology, 2011
- Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathwaysJournal of Hematology & Oncology, 2008